Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Carbylan achieves positive COR1.0 clinical trial results

Carbylan BioSurgery, a developer of device/drug combination products, has released Hydros-TA joint therapy (Hydros-TA) and Hydros positive COR1.0 clinical trial results.

Hydros-TA is a next generation viscosupplement/steroid single-injection combination product comprised of bacterially derived hyaluronic acid (HA) and gets modified to form biodegradable hydrogel beads.

The multi-center, double-blinded study is designed to assess the safety and effectiveness of a single injection of Hydros-TA or Hydros compared to Synvisc-One.

The study data showed superior pain relief and improved function in patients with pain from knee osteoarthritis using Hydros-TA when compared to Synvisc-One.

Lawson Health Research Institute Beryl & Richard Ivey Research Chair COR1.0 trial principal investigator Robert Petrella said it combines two well known treatment therapies, viscosupplementation and intra-articular corticosteroid, and provides the patient with a single, fast-acting, long-lasting therapy which appears to be effective.